Revenue Showdown: Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.

Takeda's dominance vs. Viridian's volatility in pharma revenue.

__timestampTakeda Pharmaceutical Company LimitedViridian Therapeutics, Inc.
Wednesday, January 1, 201417778240000004320000
Thursday, January 1, 201518073780000002538000
Friday, January 1, 201617320510000003337000
Sunday, January 1, 201717705310000004003000
Monday, January 1, 201820972240000008386000
Tuesday, January 1, 201932911880000004461000
Wednesday, January 1, 202031978120000001050000
Friday, January 1, 202135690060000002963000
Saturday, January 1, 202240274780000001772000
Sunday, January 1, 20234263762000000314000
Monday, January 1, 20244263762000000
Loading chart...

Unlocking the unknown

Revenue Showdown: Takeda vs. Viridian

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and Viridian Therapeutics, Inc. present a fascinating contrast. Over the past decade, Takeda has consistently demonstrated robust growth, with its revenue soaring from approximately 1.8 trillion in 2014 to over 4.2 trillion by 2023. This represents a remarkable increase of nearly 140%, underscoring Takeda's dominance in the global market.

Conversely, Viridian Therapeutics, a smaller player, has experienced a more volatile revenue trajectory. Starting at a modest 4.32 million in 2014, its revenue peaked at 8.39 million in 2018 before declining to just 314,000 in 2023. This fluctuation highlights the challenges faced by emerging biotech firms in scaling operations and achieving consistent growth.

While Takeda's financial stability is evident, Viridian's journey reflects the dynamic nature of the biotech sector, where innovation and risk go hand in hand.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025